价格

Suzhou Ribo Life Science Co., Ltd.

ACTIVE

No.168, Yuanfeng Road, Yushan Town, 江苏省苏州市, 江苏省, 中国www.ribolia.comHolding51–100 名员工成立于: 2007-01-18

概览

试验阶段分布

阶段

试验数

占比

1 期

87.5%

2 期

12.5%

试验状态分布

进行中（未招募）

12.5%

已完成

75.0%

招募中

12.5%

药物批准

暂无批准数据

资讯

Ribo Receives EMA Orphan Drug Designation for siRNA Therapeutic RBD1016 Targeting Hepatitis D Virus

- The European Medicines Agency has granted Orphan Drug Designation to RBD1016, an siRNA therapeutic developed by Ribo for treating Hepatitis D Virus infection. - RBD1016 utilizes Ribo's proprietary GalNAc-platform RiboGalSTAR™ to selectively silence key viral factors involved in HDV infection and is currently in Phase II clinical development. - HDV affects an estimated 12-20 million people globally and represents the most severe form of viral hepatitis, with limited therapeutic options currently available. - The designation provides significant regulatory and commercial incentives that enable more rapid progression to patients suffering from this rare and underserved disease.

Oct 24, 2025

返回机构列表

Suzhou Ribo Life Science Co., Ltd.

概览

试验阶段分布

试验状态分布

相关临床试验

该机构主办的试验（8）

Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD1119 in Healthy Participants

A Study of RBD1016 in CHB Participants

A Single and Multiple Ascending Doses Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RBD7022

A Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD4059 in Healthy Subjects

A trial to evaluate safety and characteristics of a substance for treatment of chronic hepatitis

A Single and Multiple Ascending Doses Study to Evaluate the Safety and Pharmacokinetics of RBD5044

A Single and Repeated Dose Escalation of RBD1016 in Subjects with Chronic Hepatitis B Virus (HBV) Infection

A Single Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of RBD1016

药物批准

资讯

Ribo Receives EMA Orphan Drug Designation for siRNA Therapeutic RBD1016 Targeting Hepatitis D Virus